Researchers at the University of Waterloo have developed a new system that could significantly speed up the discovery of new drugs and reduce the need for costly and time-consuming laboratory tests.
The new technology called Pattern to Knowledge (P2K) can predict the binding of biosequences in seconds and potentially reduce bottlenecks in drug research.
P2K uses artificial intelligence (AI) to leverage deep knowledge from data instead of relying solely on classical machine learning.
“P2K is a game changer given its ability to reveal subtle protein associations entangled in complex physiochemical environments and powerfully predict interactions based only on sequence data,” said Andrew Wong, professor, Systems Design Engineering, and Founding Director, Centre for Pattern Analysis and Machine Intelligence (CPAMI). “The ability to access this deep knowledge from proven scientific results will shift biological research going forward. P2K has the power to transform how data could be used in the future.”
Although a large amount of biological sequence data has been collected, extracting meaningful and useful knowledge hasn’t been easy. P2K algorithms tackle this challenge by disentangling multiple associations to identify and predict amino acid bindings that govern protein interactions. Since P2K is much faster than existing biosequence analysis software with almost 30 per cent better prediction accuracy, it could significantly speed up the discovery of new drugs. By drawing information from databases in the Cloud, P2K could predict how tumour proteins and potential cancer treatments would interact.
Although still in the early prototype stage, Professor Wong and his team have made the online P2K system available publicly to researchers to start identifying new bio-sequence interactions.
“Putting this AI technology in the hands of biomedical researchers will generate immediate results, which could be used for future scientific discoveries,” said Antonio Sze-To, research associate, Systems Design Engineering, and co-inventor of P2K.
Since it analyzes sequential data, the applicability of P2K isn’t limited to biomedical research. P2K could benefit the financial industry by making useful associations and predictions for smart trading or the cybersecurity sector by predicting the likelihood of a potential cyber attack.
The Latest on: Drug discovery
via Google News
The Latest on: Drug discovery
- Horizon Discovery inks exclusive pact with C4XD to deliver potential new cancer drugs on December 16, 2018 at 11:40 pm
StockMarketWire.com - Horizon Discovery Group on Monday inked an exclusive partnership ... to discover pre-clinical drug candidates using novel synthetic lethal oncology targets that Horizon had ident... […]
- Baculovirus Paves the Way for New Drug Discovery on December 16, 2018 at 10:30 pm
Baculovirus virion(BV) induced innate immunity completely eliminates the liver stage dormant hypnozoites of Plasmodium vivax in a mouse model. This can lead to the discovery of new and more effective ... […]
- Cancer Immunotherapy Drug Discovery Outsourcing Market is grow with 14.0% CAGR during the forecast time period 2018-2026 on December 14, 2018 at 3:21 am
The global cancer immunotherapy drug discovery outsourcing market size is anticipated to around USD 1.8 billion by 2026, this market is anticipated to grow with 14.0% CAGR during the forecast time per... […]
- CETSA HT in early drug discovery through screening against B-Raf and PARP1 on December 13, 2018 at 5:04 pm
We allow third-party companies to serve ads and/or collect anonymous information. These companies may use non-personally identifiable information (browser type, time and date) in order to provide adve... […]
- Drug Discovery Informatics Market - Technology, Trends, Development, Key Manufacturers Analysis and Forecast to 2025 on December 13, 2018 at 12:44 pm
Some of the key players influencing the market are PerkinElmer, Inc., Schrödinger, LLC, Certara, L.P., Infosys Limited, IBM, Collaborative Drug Discovery, Inc., Jubilant Life Sciences Ltd ... […]
- X-Chem, Almirall forge dermatology-focused drug discovery alliance on December 13, 2018 at 3:08 am
Under the terms of the agreement, X-Chem will utilize its industry-leading DNA-encoded library (DEX) screening platform and proprietary informatics tools to search for novel hits for Almirall targets. ... […]
- Killing the liver-stage malaria parasite with baculovirus: a drug discovery approach on December 12, 2018 at 7:45 am
A proportion of P. vivax sporozoites differentiate to a hypnozoite form that ultimately reactivates and proliferates leading to a blood-stage relapse. The hypnozoites are not eradicated by ... […]
- Almirall and X-Chem Announce Dermatology-Focused Drug Discovery Collaboration on December 12, 2018 at 4:15 am
X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery p... […]
- Schrödinger, TB Alliance collaborate to advance tuberculosis drug discovery on December 12, 2018 at 3:45 am
Schrödinger and TB Alliance have entered into a three-year research collaboration to enhance the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced comput... […]
via Bing News